Vimarsana
Biggest News Aggregation in the World

Page 22 - Director John News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Director John. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Director John Today - Breaking & Trending Today

Alphabet Inc. (NASDAQ:GOOG) Stake Lifted by Evermay Wealth Management LLC - Vimarsana News

Alphabet Inc. (NASDAQ:GOOG) Stake Lifted by Evermay Wealth Management LLC

Evermay Wealth Management LLC raised its stake in Alphabet Inc. (NASDAQ:GOOG – Free Report) by 3.4% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 6,855 shares of the information services provider’s stock after buying an additional 225 shares during the quarter. Evermay Wealth Management LLC’s holdings in Alphabet were worth $966,000 as of […]

Source: wkrb13.com
HC Wainwright Weighs in on Cytokinetics, Incorporated's Q2 2024 Earnings (NASDAQ:CYTK) - Vimarsana News

HC Wainwright Weighs in on Cytokinetics, Incorporated's Q2 2024 Earnings (NASDAQ:CYTK)

Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) – Equities researchers at HC Wainwright lifted their Q2 2024 earnings per share estimates for shares of Cytokinetics in a research report issued on Thursday, May 23rd. HC Wainwright analyst J. Pantginis now expects that the biopharmaceutical company will post earnings per share of ($1.16) for the quarter, up […]

Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Rating of "Moderate Buy" from Analysts - Vimarsana News

Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Rating of "Moderate Buy" from Analysts

Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) has received a consensus rating of “Moderate Buy” from the seventeen brokerages that are currently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating on the company. The average 12 month price objective among […]

Needham & Company LLC Lowers Cytokinetics (NASDAQ:CYTK) Price Target to $72.00 - Vimarsana News

Needham & Company LLC Lowers Cytokinetics (NASDAQ:CYTK) Price Target to $72.00

Cytokinetics (NASDAQ:CYTK – Free Report) had its price target reduced by Needham & Company LLC from $108.00 to $72.00 in a research report report published on Thursday, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. CYTK has been the subject of several other research reports. JMP Securities lowered their price […]

Raymond James Cuts Cytokinetics (NASDAQ:CYTK) Price Target to $70.00 - Vimarsana News

Raymond James Cuts Cytokinetics (NASDAQ:CYTK) Price Target to $70.00

Cytokinetics (NASDAQ:CYTK – Free Report) had its price objective cut by Raymond James from $92.00 to $70.00 in a report published on Thursday morning, Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock. A number of other brokerages have also recently commented on CYTK. Mizuho reduced their price target on shares […]